0001127602-19-011991.txt : 20190319
0001127602-19-011991.hdr.sgml : 20190319
20190319082633
ACCESSION NUMBER: 0001127602-19-011991
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190315
FILED AS OF DATE: 20190319
DATE AS OF CHANGE: 20190319
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BENKOWITZ MICHAEL
CENTRAL INDEX KEY: 0001673232
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26301
FILM NUMBER: 19690250
MAIL ADDRESS:
STREET 1: C/O UNITED THERAPEUTICS CORP
STREET 2: 1040 SPRING STREET
CITY: SILVER SPRING
STATE: MD
ZIP: 20910
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: UNITED THERAPEUTICS Corp
CENTRAL INDEX KEY: 0001082554
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 521984749
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1040 SPRING ST
CITY: SILVER SPRING
STATE: MD
ZIP: 20910
BUSINESS PHONE: 3016089292
MAIL ADDRESS:
STREET 1: 1040 SPRING ST
CITY: SILVER SPRING
STATE: MD
ZIP: 20910
FORMER COMPANY:
FORMER CONFORMED NAME: UNITED THERAPEUTICS CORP
DATE OF NAME CHANGE: 19990324
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2019-03-15
0001082554
UNITED THERAPEUTICS Corp
UTHR
0001673232
BENKOWITZ MICHAEL
C/O UNITED THERAPEUTICS CORPORATION
1040 SPRING STREET
SILVER SPRING
MD
20910
1
President and COO
Common Stock
1690
D
Stock Options
135.42
2019-03-15
4
A
0
187500
0
A
2023-03-15
2027-03-15
Common Stock
187500
187500
D
Stock Options
117.76
2019-03-15
4
A
0
187500
0
A
2021-03-15
2027-03-15
Common Stock
187500
187500
D
Includes 210 shares acquired on March 4, 2019, under the United Therapeutics Corporation Employee Stock Purchase Plan ("ESPP").
These stock options represent up-front equity grants covering four years of equity compensation for this named executive officer (2019 through 2022) and have been designed such that: (a) overall equity compensation expense on an annualized basis, and overall dilution, are both expected to be lower than if the Company had continued with the previous equity compensation program for four additional years; (b) the named executive officer will be incented to achieve the Company's business objectives over the four-year period; and (c) vesting is heavily weighted toward the end of the four-year period, in order to aid in retention over that timeframe.
Exercise price is equal to 115% of the closing price for the Company's common stock on the date of grant.
This award will cliff vest (100%) on March 15, 2023.
These stock options will vest in equal one-third installments on March 15, 2021, 2022 and 2023.
/s/ John S. Hess, Jr. under Power of Attorney
2019-03-18